CME Group grants 2,592 restricted shares to CTO

CME’s Chief Transformation Officer received a new restricted stock grant and surrendered shares back to the company to cover tax withholding from vesting awards.

Rhea-AI Filing Summary

CME GROUP INC. (CME) reported that Chief Transformation Officer Ken Vroman received an equity compensation award and related tax-withholding share dispositions. On September 15, 2026, he was granted 2,592 shares of Class A common stock as restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service. In connection with the vesting of previously granted restricted stock, a total of 1,211 shares of Class A common stock were surrendered to CME Group to satisfy tax withholding obligations on September 15 and 16, 2026. No Rule 10b5-1 trading plan is reported for these transactions.

Insider Trade Summary

5 transactions reported

Mixed 5 txns

Insider Vroman Ken

Role Chief Transformation Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock Class A F2	308	$272.46	$84K
Grant/Award	Common Stock Class A F1	2,592	$275.09	$713K
Tax Withholding	Common Stock Class A F2	320	$275.09	$88K
Tax Withholding	Common Stock Class A F2	309	$275.09	$85K
Tax Withholding	Common Stock Class A F2	274	$275.09	$75K

Holdings After Transaction: Common Stock Class A — 20,232 shares (Direct)

Footnotes (2)

1. F1. Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.
2. F2. Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

Key Figures

Restricted stock granted: 2,592 shares Shares surrendered for tax withholding: 1,211 shares Grant-related price: $275.09 per share +3 more

6 metrics

Restricted stock granted 2,592 shares Grant of restricted Class A common stock on September 15, 2026

Shares surrendered for tax withholding 1,211 shares Total Class A shares surrendered to CME Group for tax withholding

Grant-related price $275.09 per share Price reported for September 15, 2026 restricted stock grant and related tax surrenders

Tax withholding price (second day) $272.46 per share Price reported for September 16, 2026 tax-withholding share surrender

Tax-withholding transactions count 4 transactions Code F dispositions for tax withholding on September 15–16, 2026

Award vesting schedule 4 equal annual installments Restricted stock grant vests in four equal annual installments, subject to continued service

Key Terms

restricted stock, tax withholding obligations, Omnibus Stock Plan, surrendered to the Issuer

4 terms

restricted stock financial

"Represents a grant of restricted stock under the CME Group Omnibus Stock Plan"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

tax withholding obligations financial

"satisfy tax withholding obligations in connection with the vesting of restricted stock"

Omnibus Stock Plan financial

"grant of restricted stock under the CME Group Omnibus Stock Plan"

surrendered to the Issuer financial

"Represents shares surrendered to the Issuer to satisfy tax withholding"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did CME (CME) grant to Ken Vroman in this Form 4?

CME granted Ken Vroman 2,592 shares of Class A common stock as restricted stock on September 15, 2026, under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

How many CME (CME) shares were surrendered for tax withholding in this filing?

A total of 1,211 shares of CME Class A common stock were surrendered to CME Group to satisfy tax withholding obligations tied to the vesting of previously granted restricted stock.

Were any CME (CME) shares sold on the open market in this Form 4?

No. The dispositions reported, totaling 1,211 shares, represent shares surrendered to CME Group to satisfy tax withholding obligations, not open-market sales.

On what dates did the CME (CME) transactions for Ken Vroman occur?

The Form 4 reports a restricted stock grant on September 15, 2026, and share surrenders for tax withholding on September 15, 2026, and September 16, 2026.

Was a Rule 10b5-1 trading plan used for these CME (CME) transactions?

No. The filing indicates no Rule 10b5-1 plan for the reported grant and tax-withholding share surrenders.

What prices are associated with the CME (CME) transactions in this Form 4?

The restricted stock grant and related tax-withholding surrenders on September 15, 2026, are reported at $275.09 per share. The tax-withholding surrender on September 16, 2026, is reported at $272.46 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 04:29 PM Accepted by SEC EDGAR 09/17/2026 - 04:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vroman Ken

(Last) (First) (Middle)

20 S. WACKER DRIVE

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CME GROUP INC. [ CME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Transformation Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock Class A	09/15/2026		A(1)		2,592	A	$275.09	21,443	D
Common Stock Class A	09/15/2026		F(2)		320	D	$275.09	21,123	D
Common Stock Class A	09/15/2026		F(2)		309	D	$275.09	20,814	D
Common Stock Class A	09/15/2026		F(2)		274	D	$275.09	20,540	D
Common Stock Class A	09/16/2026		F(2)		308	D	$272.46	20,232	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock under the CME Group Omnibus Stock Plan, vesting in four equal annual installments, subject to continued service.

2. Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock previously granted to the Reporting Person.

Remarks:

	/s/ Elizabeth Hensen, as Attorney-in-Fact for Kendal Vroman	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)